{{medical}}
'''癌症标志物'''又稱'''腫瘤標誌物'''，是由[[癌細胞|癌細胞]]直接产生或由非癌細胞经癌細胞诱导产生（人體對癌細胞的反應）的物质（[[生物標記|生物標記]]）<ref>{{cite news |title=“肿瘤标志物”升高，是不是得了癌症？ |url=http://wsjkw.sh.gov.cn/zl/20200924/2d9d0e1929a94a85b9d3bbd4afb35e16.html |publisher=瑞金医院 |accessdate=2021-10-14 |archive-date=2021-10-23 |archive-url=https://web.archive.org/web/20211023192832/http://wsjkw.sh.gov.cn/zl/20200924/2d9d0e1929a94a85b9d3bbd4afb35e16.html |dead-url=no }}</ref>。癌症标志物存在於人們的血液、尿液或组织中。对于肿瘤标志物的检测可对肿瘤存在、发病过程及预后作出判断。每個腫瘤標誌物對應的癌症有所不同。肿瘤标志物水平升高可能表明患有癌症，然而也可能有其他原因導致升高。

癌症标志物可回答的问题：
* 预后：这种癌症可能继续生长？
* 诊断：我患了何种癌症？
* 预测：这种药是针对我患癌症的最佳用药吗？
* 药效学：对我来说此药的最佳用量是多少？
* 复发：癌症会再次发作吗？

== 常見的腫瘤標誌物 ==
{|class="wikitable"
! 腫瘤標誌物 !! 有關的癌症
|-
| [[Α-胎兒蛋白|Α-胎兒蛋白]] (AFP) || [[生殖细胞瘤|生殖细胞瘤]], [[肝細胞癌|肝細胞癌]]<ref name=Territo2008>[https://books.google.com/books?id=pobC8zHbWzwC&pg=PA746 Page 746] {{Wayback|url=https://books.google.com/books?id=pobC8zHbWzwC&pg=PA746 |date=20140819151608 }} in: 
Title	Manual of clinical oncology
Spiral manual
Manual of Clinical Oncology
Lippincott Manual Series
Authors	Dennis Albert Casciato, Mary C. Territo
Editors	Dennis Albert Casciato, Mary C. Territo
Contributor	Mary C. Territo
Edition	6, illustrated
Publisher	Lippincott Williams & Wilkins, 2008
{{ISBN|0-7817-6884-5}}, {{ISBN|978-0-7817-6884-9}}</ref>
|-
| [[CA_15-3|CA 15-3]] || [[乳癌|乳癌]]<ref>{{cite journal |doi=10.1093/annonc/mdl492 |title=CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials |year=2006 |last1=Keshaviah |first1=A |last2=Dellapasqua |first2=S |last3=Rotmensz |first3=N |last4=Lindtner |first4=J |last5=Crivellari |first5=D |last6=Collins |first6=J |last7=Colleoni |first7=M |last8=Thurlimann |first8=B |last9=Mendiola |first9=C |last10=Aebi |first10=S |last11=Price |first11=K. |last12=Pagani |first12=O |last13=Simoncini |first13=E |last14=Castiglione Gertsch |first14=M |last15=Gelber |first15=R. |last16=Coates |first16=A. |last17=Goldhirsch |first17=A |journal=Annals of Oncology |volume=18 |issue=4 |pages=701–8 |pmid=17237474|display-authors=8 |doi-access=free }}</ref>
|-
| [[Ca_27.29|CA27.29]] || [[乳癌|乳癌]]<ref>{{cite web |title=Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012 |url=http://www.medterms.com/script/main/art.asp?articlekey=39199 |access-date=2021-10-14 |archive-date=2014-02-25 |archive-url=https://web.archive.org/web/20140225091948/http://www.medterms.com/script/main/art.asp?articlekey=39199 |dead-url=no }}</ref>
|-
| [[CA19-9|CA19-9]] ||[[胰臟癌|胰臟癌]]、[[大腸癌|大腸癌]]、[[胃肠道癌|胃肠道癌]].<ref>[https://gpnotebook.co.uk/simplepage.cfm?ID=-80412627 gpnotebook.co.uk > ca-19-9] {{Wayback|url=https://gpnotebook.co.uk/simplepage.cfm?ID=-80412627 |date=20120426000657 }} Retrieved November 2011</ref>
|-
| [[CA-125|CA-125]] || [[卵巢癌|卵巢癌]],<ref name="pmid18990955">{{cite journal |vauthors=Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R | title = Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre | journal = Ir Med J | volume = 101 | issue = 8 | pages = 245–7 |date=September 2008 | pmid = 18990955 }}</ref>、[[子宫内膜癌|子宫内膜癌]], [[输卵管瘤|输卵管瘤]], [[肺癌|肺癌]], [[乳癌|乳癌]]和[[胃肠道癌|胃肠道癌]].<ref name="pmid10228898">{{cite journal |vauthors=Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB | title = CA 125: the past and the future | journal = Int. J. Biol. Markers | volume = 13 | issue = 4 | pages = 179–87 | year = 1998 | pmid = 10228898 | doi = 10.1177/172460089801300402}}</ref>、[[子宮內膜異位症|子宮內膜異位症]].<ref name="pmid17804443">{{cite journal |vauthors=Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M | title = Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax | journal = Eur. Respir. J. | volume = 31 | issue = 1 | pages = 140–2 |date=January 2008 | pmid = 17804443 | doi = 10.1183/09031936.00094206 | doi-access = free }}</ref>
|-
| [[降鈣素|降鈣素]] || [[甲狀腺髓質癌|甲狀腺髓質癌]]
|-
| {{link-en|Calretinin}} || [[間皮瘤|間皮瘤]], [[性腺间质肿瘤|性腺间质肿瘤]], {{link-en|adrenocortical carcinoma}}, [[滑膜肉瘤|滑膜肉瘤]]<ref name=Territo2008/>
|-
| [[癌胚抗原|癌胚抗原]] || [[胃肠道癌|胃肠道癌]], [[子宮頸癌|子宮頸癌]], [[肺癌|肺癌]], [[卵巢癌|卵巢癌]], [[乳癌|乳癌]], [[urinary_tract_cancer|urinary tract cancer]]<ref name=Territo2008/>
|-
| [[CD34|CD34]] || {{link-en|hemangiopericytoma}}/{{link-en|solitary fibrous tumor}}, [[多形性脂肪瘤|多形性脂肪瘤]], [[胃腸道基質腫瘤|胃腸道基質腫瘤]], {{link-en|dermatofibrosarcoma protuberans}}<ref name=Territo2008/>
|-
| {{link-en|CD99}}[[MIC_2|MIC 2]] || [[尤文氏肉瘤|尤文氏肉瘤]], {{link-en|primitive neuroectodermal tumor}}, {{link-en|hemangiopericytoma}}/{{link-en|solitary fibrous tumor}}, [[滑膜肉瘤|滑膜肉瘤]], [[淋巴瘤|淋巴瘤]], [[白血病|白血病]], [[性腺间质肿瘤|性腺间质肿瘤]]<ref name=Territo2008/>
|-
| {{link-en|CD117}} || [[胃腸道基質腫瘤|胃腸道基質腫瘤]], {{link-en|mastocytosis}}, {{link-en|seminoma}}<ref name=Territo2008/>
|-
| {{link-en|Chromogranin}} || [[神經內分泌腫瘤|神經內分泌腫瘤]]<ref name=Territo2008/>
|-
| Chromosomes 3, 7, 17, and 9p21 || [[膀胱癌|膀胱癌]]<ref>{{cite web |url=http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers |title=Tumor Markers |access-date=June 6, 2013 |archive-date=2015-02-25 |archive-url=https://web.archive.org/web/20150225053058/http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers |dead-url=no }}</ref>
|-
| {{link-en|Cytokeratin}} (TPA, TPS, Cyfra21-1)  ||[[癌|癌]]、[[肉瘤|肉瘤]]<ref name=Territo2008/>
|-
| {{link-en|Desmin}} || [[smooth_muscle_sarcoma|smooth muscle sarcoma]], [[横纹肌肉瘤|横纹肌肉瘤]], {{link-en|endometrial stromal sarcoma}}<ref name=Territo2008/>
|-
| {{link-en|Epithelial membrane antigen}} (EMA) ||[[癌|癌]]、{{link-en|meningioma}}、[[肉瘤|肉瘤]]<ref name=Territo2008/>
|-
| {{link-en|Factor VIII}}, {{link-en|CD31}} [[FL1_(protein)|FL1]] || [[vascular_sarcoma|vascular sarcoma]]<ref name=Territo2008/>
|-
| {{link-en|Glial fibrillary acidic protein }} (GFAP) || [[神經膠質瘤|神經膠質瘤]] ({{link-en|astrocytoma}}, {{link-en|ependymoma}})<ref name=Territo2008/>
|-
| [[Gross_cystic_disease_fluid_protein|Gross cystic disease fluid protein]] (GCDFP-15) || [[乳癌|乳癌]], [[卵巢癌|卵巢癌]], {{link-en|salivary gland cancer}}<ref name=Territo2008/>
|-
| {{link-en|hPG80}} || [[乳癌|乳癌]], [[卵巢癌|卵巢癌]], [[前列腺癌|前列腺癌]], [[腎癌|腎癌]], [[大腸癌|大腸癌]], [[肝癌|肝癌]]
|-
| {{link-en|HMB-45}} || [[黑色素瘤|黑色素瘤]], {{link-en|PEComa}} (例如 {{link-en|angiomyolipoma}}), {{link-en|clear cell adenocarcinoma}}, {{link-en|adrenocortical carcinoma}}<ref name=Territo2008/>
|-
| [[人绒毛膜促性腺激素|人绒毛膜促性腺激素]] (hCG) || [[妊娠滋养细胞疾病|妊娠滋养细胞疾病]], [[生殖细胞瘤|生殖细胞瘤]], [[绒毛膜癌|绒毛膜癌]]<ref name=Territo2008/>
|-
| [[抗体|抗体]] || [[淋巴瘤|淋巴瘤]], [[白血病|白血病]]<ref name=Territo2008/>
|-
| [[激活素与抑制素|激活素与抑制素]] || [[性腺间质肿瘤|性腺间质肿瘤]], {{link-en|adrenocortical carcinoma}}, {{link-en|hemangioblastoma}}<ref name=Territo2008/>
|-
| [[角蛋白|角蛋白]] || [[癌|癌]], [[肉瘤|肉瘤]]<ref name=Territo2008/>
|-
| [[淋巴细胞|淋巴细胞]]|| [[淋巴瘤|淋巴瘤]], [[白血病|白血病]]<ref name=Territo2008/>
|-
| {{link-en|MART-1}} (Melan-A) || [[黑色素瘤|黑色素瘤]],{{link-en|adrenocortical carcinoma}}、[[gonadal_tumor|gonadal tumor]]<ref name=Territo2008/>
|-
| {{link-en|Myo D1}} || [[横纹肌肉瘤|横纹肌肉瘤]], {{link-en|small, round, blue cell tumour}}<ref name=Territo2008/>
|-
| [[muscle-specific_actin|muscle-specific actin]] (MSA) || {{link-en|myosarcoma}} ([[平滑肌肉瘤|平滑肌肉瘤]], [[横纹肌肉瘤|横纹肌肉瘤]])<ref name=Territo2008/>
|-
| {{link-en|neurofilament}} || [[神經內分泌腫瘤|神經內分泌腫瘤]], [[小细胞癌|小细胞癌]]<ref name=Territo2008/>
|-
| {{link-en|neuron-specific enolase}} (NSE) || [[神經內分泌腫瘤|神經內分泌腫瘤]], [[小细胞癌|小细胞癌]], [[乳癌|乳癌]]<ref name=Territo2008/>
|-
| {{link-en|placental alkaline phosphatase}} (PLAP) || {{link-en|seminoma}}, [[无性细胞瘤|无性细胞瘤]], [[胚胎性癌|胚胎性癌]]<ref name=Territo2008/>
|-
| [[前列腺特异抗原|前列腺特异抗原]] (PSA) || [[前列腺|前列腺]]<ref name=Territo2008/>
|-
| [[蛋白酪氨酸磷酸酶C型受體|蛋白酪氨酸磷酸酶C型受體]] (CD45) || [[淋巴瘤|淋巴瘤]], [[白血病|白血病]], {{link-en|histiocytic sarcoma}}<ref name=Territo2008/>
|-
| [[S100蛋白|S100蛋白]] || [[黑色素瘤|黑色素瘤]], [[肉瘤|肉瘤]] ({{link-en|neurosarcoma}}, [[脂肪瘤|脂肪瘤]], {{link-en|chondrosarcoma}}), {{link-en|astrocytoma}}, [[胃腸道基質腫瘤|胃腸道基質腫瘤]], {{link-en|salivary gland cancer}}, {{link-en|adenocarcinoma}}, [[histiocytic_tumor|histiocytic tumor]] ([[樹突狀細胞|樹突狀細胞]], [[巨噬细胞|巨噬细胞]])<ref name=Territo2008/>
|-
| [[smooth_muscle_actin|smooth muscle actin]] (SMA) || [[胃腸道基質腫瘤|胃腸道基質腫瘤]], [[平滑肌肉瘤|平滑肌肉瘤]], {{link-en|PEComa}}<ref name=Territo2008/>
|-
| [[突觸素|突觸素]] || [[神經內分泌腫瘤|神經內分泌腫瘤]]<ref name=Territo2008/>
|-
| [[胸苷激酶|胸苷激酶]] || [[淋巴瘤|淋巴瘤]], [[白血病|白血病]], [[肺癌|肺癌]], [[前列腺癌|前列腺癌]]
|-
| {{link-en|thyroglobulin}} (Tg) || [[甲狀腺癌|甲狀腺癌]]<ref name=Territo2008/>
|-
| {{link-en|thyroid transcription factor-1}} (TTF-1) || [[甲狀腺癌|甲狀腺癌]], [[肺癌|肺癌]]<ref name=Territo2008/>
|-
| {{link-en|Tumor M2-PK}}  || [[大腸癌|大腸癌]],<ref name=Haug2007>{{cite journal |doi=10.1038/sj.bjc.6603712 |title=Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients |year=2007 |last1=Haug |first1=U |last2=Rothenbacher |first2=D |last3=Wente |first3=M N |last4=Seiler |first4=C M |last5=Stegmaier |first5=C |last6=Brenner |first6=H |journal=British Journal of Cancer |pmid=17406361 |pmc=2360192 |volume=96 |issue=9 |pages=1329–34}}</ref> [[乳癌|乳癌]],<ref>{{cite journal |pmid=11326672 |year=2000 |last1=Lüftner |first1=D |last2=Mesterharm |first2=J |last3=Akrivakis |first3=C |last4=Geppert |first4=R |last5=Petrides |first5=PE |last6=Wernecke |first6=KD |last7=Possinger |first7=K |title=Tumor type M2 pyruvate kinase expression in advanced breast cancer |volume=20 |issue=6D |pages=5077–82 |journal=Anticancer Research}}</ref><ref>{{cite journal |pmid=20592362 |year=2010 |last1=Benesch |first1=C |last2=Schneider |first2=C |last3=Voelker |first3=HU |last4=Kapp |first4=M |last5=Caffier |first5=H |last6=Krockenberger |first6=M |last7=Dietl |first7=J |last8=Kammerer |first8=U |last9=Schmidt |first9=M |title=The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer |volume=30 |issue=5 |pages=1689–94 |journal=Anticancer Research }}</ref> {{link-en|renal cell carcinoma}}<ref>{{cite journal |pmid=11326675 |year=2000 |last1=Oremek |first1=GM |last2=Sapoutzis |first2=N |last3=Kramer |first3=W |last4=Bickeböller |first4=R |last5=Jonas |first5=D |title=Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma |volume=20 |issue=6D |pages=5095–8 |journal=Anticancer Research}}</ref><ref>{{cite journal |pmid=10470199 |year=1999 |last1=Wechsel |first1=HW |last2=Petri |first2=E |last3=Bichler |first3=KH |last4=Feil |first4=G |title=Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK) |volume=19 |issue=4A |pages=2583–90 |journal=Anticancer Research}}</ref> [[肺癌|肺癌]],<ref>{{cite journal |pmid=12624710 |year=2003 |last1=Schneider |first1=J |last2=Peltri |first2=G |last3=Bitterlich |first3=N |last4=Philipp |first4=M |last5=Velcovsky |first5=HG |last6=Morr |first6=H |last7=Katz |first7=N |last8=Eigenbrodt |first8=E |title=Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients |volume=2 |issue=4 |pages=185–91 |doi=10.1007/s102380300005 |journal=Clinical and Experimental Medicine}}</ref><ref>{{cite journal |pmid=17882813 |year=2007 |last1=Oremek |first1=G |last2=Kukshaĭte |first2=R |last3=Sapoutzis |first3=N |last4=Ziolkovski |first4=P |title=The significance of TU M2-PK tumor marker for lung cancer diagnostics |volume=85 |issue=7 |pages=56–8 |journal=Klinicheskaia Meditsina}}</ref> [[胰臟癌|胰臟癌]],<ref>{{cite journal |pmid=11326648 |year=2000 |last1=Hardt |first1=PD |last2=Ngoumou |first2=BK |last3=Rupp |first3=J |last4=Schnell-Kretschmer |first4=H |last5=Kloer |first5=HU |title=Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer |volume=20 |issue=6D |pages=4965–8 |journal=Anticancer Research}}</ref> [[食道癌|食道癌]],<ref name="DoiMEGbef">{{cite journal |doi=10.1097/MEG.0b013e3280102f78 |pmid=17301655 |title=Tumour M2-pyruvate kinase: A gastrointestinal cancer marker |year=2007 |last1=Kumar |first1=Yogesh |last2=Tapuria |first2=Niteen |last3=Kirmani |first3=Naveed |last4=Davidson |first4=Brian R. |journal=European Journal of Gastroenterology & Hepatology |volume=19 |issue=3 |pages=265–276}}</ref> [[胃癌|胃癌]],<ref name="DoiMEGbef" />[[子宮頸癌|子宮頸癌]],<ref>{{cite journal |pmid=15210041 |year=2004 |last1=Kaura |first1=B |last2=Bagga |first2=R |last3=Patel |first3=FD |title=Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma |volume=30 |issue=3 |pages=193–6 |doi=10.1111/j.1447-0756.2004.00187.x |journal=The Journal of Obstetrics and Gynaecology Research}}</ref> [[卵巢癌|卵巢癌]],<ref>{{cite journal |pmid=17479666 |year=2007 |last1=Ahmed |first1=AS |last2=Dew |first2=T |last3=Lawton |first3=FG |last4=Papadopoulos |first4=AJ |last5=Devaja |first5=O |last6=Raju |first6=KS |last7=Sherwood |first7=RA |title=M2-PK as a novel marker in ovarian cancer. A prospective cohort study |volume=28 |issue=2 |pages=83–8 |journal=European Journal of Gynaecological Oncology}}</ref>
|-
| [[波形蛋白|波形蛋白]] || [[肉瘤|肉瘤]], {{link-en|renal cell carcinoma}}, [[子宫内膜癌|子宫内膜癌]], [[肺癌|肺癌]], [[淋巴瘤|淋巴瘤]], [[白血病|白血病]], [[黑色素瘤|黑色素瘤]]<ref name=Territo2008/>
|}
===分子癌症标志物===
{| border="1"| class="wikitable"
|-
! '''肿瘤类型''' !! '''生物标志物'''
|-
|rowspan="2" | 乳腺
| ER（雌激素受体）<ref name="table">{{cite web |title=Table of Pharmacogenomic Biomarkers in Drug Labels |url=http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. |publisher=U.S Food and Drug Administration}}</ref><ref name="two">{{cite web |title=Tumor Markers Fact Sheet |url=http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf |publisher=American Cancer Society |format=PDF |accessdate=2013-07-09 |archive-date=2012-11-05 |archive-url=https://web.archive.org/web/20121105101624/http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf |dead-url=no }}</ref> 
|-
| HER-2/neu<ref name="table"/><ref name="two"/>
|-
|rowspan="3" |结直肠
| EGFR<ref name="table"/><ref name="two"/>
|-
| KRAS<ref name="table"/><ref name="three">{{cite web |last=Lenz |first=Heinz-Josef |title=Established Biomarkers in Colon Cancer |url=http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2009/09 EdBk.GI.Colo.04.pdf |publisher=American Society of Clinical Oncology’s 2009 Educational Book |format=PDF }}{{dead link|date=2018年3月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
| UGT1A1<ref name="table"/><ref name="three"/>
|-
|胃
| HER-2/neu<ref name="table"/>
|-
|胃腸道基質腫瘤
| c-KIT<ref name="table"/><ref>{{cite journal |author=Gonzalez RS, Carlson G, Page AJ, Cohen C |title=Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome |url=https://archive.org/details/sim_american-journal-of-clinical-pathology_2011-07_136_1/page/74 |journal=Am. J. Clin. Pathol. |volume=136 |issue=1 |pages=74–80 |pmid=21685034 |doi=10.1309/AJCP9KHD7DCHWLMO |date=July 2011}}</ref> 
|-
|rowspan="8" |白血病/淋巴瘤
|CD20抗原<ref name="table"/><ref>{{cite journal |author=Tam CS, Otero-Palacios J, Abruzzo LV, ''et al.'' |title=Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients |journal=Br. J. Haematol. |volume=141 |issue=1 |pages=36–40 |pmid=18324964 |doi=10.1111/j.1365-2141.2008.07012.x |date=April 2008}}</ref> 
|-
|CD30<ref name="table"/><ref>{{cite journal |author=Zhang M, Yao Z, Patel H, ''et al.'' |title=Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=104 |issue=20 |pages=8444–8 |pmid=17488826 |pmc=1895969 |doi=10.1073/pnas.0702496104 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=17488826|date=May 2007}}</ref> 
|-
|FIP1L1-PDGRFα<ref name="table"/><ref>{{cite journal |author=Yamada Y, Sanchez-Aguilera A, Brandt EB, ''et al.'' |title=FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome |journal=Blood |volume=112 |issue=6 |pages=2500–7 |pmid=18539901 |doi=10.1182/blood-2007-11-126268 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18539901 |date=September 2008 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|PDGFR<ref name="table"/><ref>{{cite journal |author=Nimer SD |title=Myelodysplastic syndromes |journal=Blood |volume=111 |issue=10 |pages=4841–51 |pmid=18467609 |doi=10.1182/blood-2007-08-078139 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18467609 |date=May 2008 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|费城染色体（BCR/ABL）<ref name="table"/><ref>{{cite journal |author=Ottmann O, Dombret H, Martinelli G, ''et al.'' |title=Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study |journal=Blood |volume=110 |issue=7 |pages=2309–15 |pmid=17496201 |doi=10.1182/blood-2007-02-073528 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=17496201 |date=October 2007 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{cite journal |author=Boulos N, Mulder HL, Calabrese CR, ''et al.'' |title=Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia |journal=Blood |volume=117 |issue=13 |pages=3585–95 |pmid=21263154 |pmc=3072880 |doi=10.1182/blood-2010-08-301267 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=21263154 |date=March 2011 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|PML/RARα<ref name="table"/><ref>{{cite journal |author=O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM |title=Regulation of S100A10 by the PML-RAR-α oncoprotein |journal=Blood |volume=117 |issue=15 |pages=4095–105 |pmid=21310922 |doi=10.1182/blood-2010-07-298851 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=21310922 |date=April 2011 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|TPMT<ref name="table"/><ref>{{cite journal |author=Duffy MJ, Crown J |title=A personalized approach to cancer treatment: how biomarkers can help |journal=Clin. Chem. |volume=54 |issue=11 |pages=1770–9 |pmid=18801934 |doi=10.1373/clinchem.2008.110056 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=18801934 |date=November 2008 }}{{Dead link|date=2020年3月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|UGT1A1<ref name="table"/><ref>{{cite journal |author=Ribrag V, Koscielny S, Casasnovas O, ''et al.'' |title=Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis |journal=Blood |volume=113 |issue=14 |pages=3307–13 |pmid=18768784 |doi=10.1182/blood-2008-03-148874 |url=http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=18768784 |date=April 2009 }}{{Dead link|date=2020年2月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 
|-
|rowspan="3" | 肺
|ALK<ref name="table"/><ref>{{cite journal |author=Li Y, Ye X, Liu J, Zha J, Pei L |title=Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors |journal=Neoplasia |volume=13 |issue=1 |pages=1–11 |pmid=21245935 |pmc=3022423 |url=http://www.neoplasia.com/abstract.php?msid=3835 |date=January 2011 }}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name="lo">{{cite journal |author=Pao W, Girard N |title=New driver mutations in non-small-cell lung cancer |journal=Lancet Oncol. |volume=12 |issue=2 |pages=175–80 |pmid=21277552 |doi=10.1016/S1470-2045(10)70087-5 |url=http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(10)70087-5 |date=February 2011 |access-date=2013-07-09 |archive-date=2020-08-09 |archive-url=https://web.archive.org/web/20200809055954/https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(10)70087-5 |dead-url=no }}</ref> 
|-
|EGFR<ref name="table"/><ref name="two"/>
|-
|KRAS<ref name="table"/><ref name="two"/>
|-
|黑色素瘤
|BRAF<ref name="table"/><ref name="lo"/>
|}

生物标志物的其它例子：
*在癌症中抑癌基因表达缺失
**例子：[[BRCA1|BRCA1]]、[[BRCA2|BRCA2]]
*RNA
**例子：[[信使核糖核酸|信使核糖核酸]]、[[微RNA|微RNA]] <ref>{{cite journal |author=Bartels CL, Tsongalis GJ |title=MicroRNAs: novel biomarkers for human cancer |journal=Clin. Chem. |volume=55 |issue=4 |pages=623–31 |pmid=19246618 |doi=10.1373/clinchem.2008.112805 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=19246618 |date=April 2009 }}{{Dead link|date=2020年3月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>
*存在于体液或组织中的蛋白质。
**例子：[[前列腺特异性抗原|前列腺特异性抗原]]和[[CA-125|CA-125]]

==参考文献==
{{reflist}}

[[Category:肿瘤学|Category:肿瘤学]]